Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Teva Pharmaceutical Industries Ltd (NY: TEVA)
18.46 USD  -0.56 (-2.94%)
Official Closing Price  /  Updated: 7:54 PM EST, Dec 14, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 9,608,800
Open 18.86
Bid (Size) 18.27 (6)
Ask (Size) 18.57 (6)
Prev. Close 19.02
Today's Range 18.28 - 19.16
52wk Range 15.70 - 25.96
Shares Outstanding 1,018,482,488
Dividend Yield 0.39%
Performance
YTD
-3.40%
-3.40%
1 Month
-18.57%
-18.57%
3 Month
-19.21%
-19.21%
6 Month
-22.31%
-22.31%
1 Year
+6.71%
+6.71%
Top News
More News
Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications
Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved HERZUMA® (trastuzumab-pkrb), a... Read More
from Business Wire News Releases
BioSim Pharmaceuticals to Attend JP Morgan Healthcare Conference in San Francisco
Held annually alongside Biotech Showcase and OneMed Forum, the JP Morgan conference is one of the largest and most informative healthcare symposiums in the industry. BioSim will be meeting throughout... Read More
from Business Wire News Releases
More News
Read More
Detailed Research: Economic Perspectives on American Tower Corporation (REIT), Ligand Pharmaceuticals, Teva Pharmaceutical Industries, Cummins, Alexander's, and Korea Electric Power — What Drives Grow
from GlobeNewswire News Releases
Teva Pharm to move headquarters to Tel Aviv
category companyNews
from Reuters: Company News
February 2019 Options Now Available For Teva Pharmaceutical Industries (TEVA)
category Stocks
from Market News Video
Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications
from Business Wire News Releases
Teva Pharmaceutical Industries Enters Oversold Territory (TEVA)
category Stocks
from Market News Video
Generic drug stocks slammed by report of expanded price-fixing probe
category ENDP , MYL , PFE , and 15 more.
from MarketWatch
ACWX, NTES, BAP, TEVA: Large Inflows Detected at ETF
category ETFs
from ETF Channel
Here's Why Corcept Therapeutics Rose 18.6% in November
category Market News , TEVA , CORT
from Motley Fool
Why Teva Pharmaceutical Industries, Tivity Health, and Marine Products Slumped Today
category TVTY , Market News , TEVA , and 1 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X